Novogen Current Ratio 2006-2021 | KZIA

Novogen current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Novogen Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.02B $0.01B 3.53
2020-12-31 $0.02B $0.00B 7.57
2020-06-30 $0.01B $0.00B 2.10
2019-12-31 $0.01B $0.00B 2.44
2019-06-30 $0.01B $0.00B 3.95
2018-06-30 $0.01B $0.00B 2.38
2017-12-31 $0.01B $0.01B 2.09
2017-06-30 $0.02B $0.00B 3.63
2016-12-31 $0.02B $0.00B 9.80
2016-06-30 $0.05B $0.00B 23.86
2015-12-31 $0.03B $0.00B 27.17
2015-06-30 $0.03B $0.00B 25.29
2014-12-31 $0.01B $0.00B 3.66
2014-06-30 $0.00B $0.00B 0.81
2013-12-31 $0.01B $0.00B 1.61
2013-06-30 $0.00B $0.00B 1.85
2012-12-31 $0.00B $0.00B 3.34
2012-06-30 $0.01B $0.00B 2.32
2011-12-31 $0.01B $0.01B 2.88
2011-06-30 $0.01B $0.01B 1.54
2010-12-31 $0.01B $0.01B 2.43
2010-06-30 $0.02B $0.01B 3.21
2009-12-31 $0.02B $0.00B 5.19
2009-06-30 $0.03B $0.01B 4.25
2008-12-31 $0.04B $0.01B 6.54
2008-06-30 $0.04B $0.01B 5.81
2007-12-31 $0.05B $0.01B 7.64
2007-06-30 $0.04B $0.01B 7.83
2006-12-31 $0.04B $0.01B 8.02
2006-06-30 $0.03B $0.01B 7.09
2005-12-31 $0.04B $0.01B 8.04
2005-06-30 $0.04B $0.01B 8.49
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.141B $0.011B
Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Kazia Therapeutics Limited, formerly known as Novogen Limited, is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76